Out of 1,500 volunteers that participated in the US-joint Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) clinical trial test, 200 were on Monday certificated after a one year observation revealed that they did not develop any symptoms from the vaccine.
During a program held on Monday, January 18 at the Redemption Hospital, which brought together local and international staff of PREVAIL, Mr. Anthony S. Fauci, M.D., Director of the US National Institute of Allergy and Infectious Diseases (NIAID), expressed gratitude to health workers, including staff of PREVAIL, for the level of progress in the study.
...